novo nordisk eli lilly

Order byBest matchMost fresh

Eli Lilly, Novo Nordisk and Zepbound

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

· 2d · on MSN

· 21h

Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?

· 1d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Novo Nordisk: A Strategy With High Potential For Volatile Times

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

pharmaphorum1d

Novo Nordisk builds case for Norditropin successor

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as effective as a daily shot of Norditropin (somatropin) in children born small for gestational age (SGA), Noonan syndrome (NS), or with idiopathic short stature (ISS).

6don MSN

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

6don MSN

Down Nearly 20%: Should You Buy the Dip on Eli Lilly?

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo Nordisk's share is decreasing.